A phase II trial was started to document the effects of inhibiting VAP-1 (BI 1467335) in patients with NASH (271); however, the research company announced that it has stopped developing this molecule in NASH due to the risk of drug interactions.1 The gene discussed is AOC3; the disease is metabolic dysfunction-associated steatohepatitis.